Shares of Inovio Pharmaceuticals jumped about 20% this morning after the biotech said it had hit the mark on the primary endpoint for its mid-stage study of VGX-3100, an experimental therapy designed to eliminate precancerous cervical lesions.

…read more

Source: Inovio vs. Feuerstein, Round II: Biotech claims PhII success for VGX-3100


0 No comments